|
Jun 27
|
2 Beaten-Down Stocks to Avoid
|
|
Jun 26
|
Sarepta Therapeutics (NasdaqGS:SRPT) Faces Shipment Suspension Amid Safety Update
|
|
Jun 25
|
Sarepta Therapeutics Is Already Down 86% This Year. And The Other Shoe Just Dropped.
|
|
Jun 25
|
TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT
|
|
Jun 24
|
Sarepta Viral Vector Gets FDA Platform Technology Designation
|
|
Jun 24
|
Sarepta Therapeutics (SRPT) Tumbles 44% W/W as Analyst Cuts Price Target by 63%
|
|
Jun 20
|
Gene Therapy Stocks Fall Amid More Turmoil at FDA
|
|
Jun 20
|
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
|
|
Jun 20
|
2 Growth Stocks with All-Star Potential and 1 to Ignore
|
|
Jun 19
|
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
|
|
Jun 18
|
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
|
|
Jun 17
|
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation
|
|
Jun 17
|
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
|
|
Jun 17
|
Company News for Jun 17, 2025
|
|
Jun 17
|
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
|
|
May 21
|
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
|
|
May 21
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
|
|
May 20
|
High Growth Tech Stocks In The US Market To Watch
|
|
May 20
|
3 Stocks Investors May Be Undervaluing By Up To 43.5%
|
|
May 19
|
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
|